Context Peptidylglycine-alpha-amidating monooxygenase (PAM) is a critical enzyme in the endocrine system responsible for activation, by amidation, of bioactive peptides.Objective To define the clinical phenotype of carriers of genetic mutations associated with impaired PAM-amidating activity (PAM-AMA).Design We used genetic and phenotypic data from cohort studies: the Malm & ouml; Diet and Cancer (MDC; 1991-1996; reexamination in 2002-2012), the Malm & ouml; Preventive Project (MPP; 2002-2006), and the UK Biobank (UKB; 2012).Setting Exome-wide association analysis was used to identify loss-of-function (LoF) variants associated with reduced PAM-AMA and subsequently used for association with the outcomes.Patients or Other Participants This study included n similar to 4500 participants from a subcohort of the MDC (MDC-Cardiovascular cohort), n similar to 4500 from MPP, and n similar to 300,000 from UKB.Main Outcome Measures Endocrine-metabolic traits suggested by prior literature, muscle mass, muscle function, and sarcopenia.Results Two LoF variants in the PAM gene, Ser539Trp (minor allele frequency: 0.7%) and Asp563Gly (5%), independently contributed to a decrease of 2.33 [95% confidence interval (CI): 2.52/2.15; P = 2.5E-140] and 0.98 (1.04/0.92; P = 1.12E-225) SD units of PAM-AMA, respectively. The cumulative effect of the LoF was associated with diabetes, reduced insulin secretion, and higher levels of GH and IGF-1. Moreover, carriers had reduced muscle mass and function, followed by a higher risk of sarcopenia. Indeed, the Ser539Trp mutation increased the risk of sarcopenia by 30% (odds ratio 1.31; 95% CI: 1.16/1.47; P = 9.8E-06), independently of age and diabetes.Conclusion PAM-AMA genetic deficiency results in a prediabetic sarcopenic phenotype. Early identification of PAM LoF carriers would allow targeted exercise interventions and calls for novel therapies that restore enzymatic activity.

Deficiency of Peptidylglycine-alpha-amidating Monooxygenase, a Cause of Sarcopenic Diabetes Mellitus

Giontella, Alice;Fava, Cristiano;
2024-01-01

Abstract

Context Peptidylglycine-alpha-amidating monooxygenase (PAM) is a critical enzyme in the endocrine system responsible for activation, by amidation, of bioactive peptides.Objective To define the clinical phenotype of carriers of genetic mutations associated with impaired PAM-amidating activity (PAM-AMA).Design We used genetic and phenotypic data from cohort studies: the Malm & ouml; Diet and Cancer (MDC; 1991-1996; reexamination in 2002-2012), the Malm & ouml; Preventive Project (MPP; 2002-2006), and the UK Biobank (UKB; 2012).Setting Exome-wide association analysis was used to identify loss-of-function (LoF) variants associated with reduced PAM-AMA and subsequently used for association with the outcomes.Patients or Other Participants This study included n similar to 4500 participants from a subcohort of the MDC (MDC-Cardiovascular cohort), n similar to 4500 from MPP, and n similar to 300,000 from UKB.Main Outcome Measures Endocrine-metabolic traits suggested by prior literature, muscle mass, muscle function, and sarcopenia.Results Two LoF variants in the PAM gene, Ser539Trp (minor allele frequency: 0.7%) and Asp563Gly (5%), independently contributed to a decrease of 2.33 [95% confidence interval (CI): 2.52/2.15; P = 2.5E-140] and 0.98 (1.04/0.92; P = 1.12E-225) SD units of PAM-AMA, respectively. The cumulative effect of the LoF was associated with diabetes, reduced insulin secretion, and higher levels of GH and IGF-1. Moreover, carriers had reduced muscle mass and function, followed by a higher risk of sarcopenia. Indeed, the Ser539Trp mutation increased the risk of sarcopenia by 30% (odds ratio 1.31; 95% CI: 1.16/1.47; P = 9.8E-06), independently of age and diabetes.Conclusion PAM-AMA genetic deficiency results in a prediabetic sarcopenic phenotype. Early identification of PAM LoF carriers would allow targeted exercise interventions and calls for novel therapies that restore enzymatic activity.
2024
diabetes
sarcopenia
genetics
PAM
insulin secretion
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11562/1142206
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? 0
social impact